OcuSciences, Inc., is a medical diagnostic device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, before irreversible cell death becomes visible.
OcuSciences plans to establish RMA as a standard tool for detecting and monitoring retinal metabolic dysfunction in primary eye care practices throughout the world. Our mission is to assist in the early detection and monitoring of retinal disease.
The device, OcuMet Beacon, is being developed to provide a high quality fundus photograph and using the RMA technology, provide a metabolic signature of the health of retinal cells. We are currently focused on the investigation of ocular manifestations of diabetes and therapies aimed at treating them. At the earliest stages of diabetic eye disease, before clinically visible complications are present, there is increased oxidative stress and mitochondrial dysfunction present in the retinal cells. We are developing RMA to detect mitochondrial dysfunction in a number of retinal diseases, including in diabetics with and without retinopathy, with the latter having even more mitochondrial dysfunction. Thus, RMA is being designed as the first non-invasive, rapid, easy-to-use, and affordable tool to detect early retinal disease, including the earliest retinal complications of diabetes.
More information can be found on our product website below.Click Here